Lucrin Depot
 |
Leuprolide Actetate for Depot Suspension
Leuprolide actetate is a synthetic nonapeptide anolog of naturally
occurring genodotropin releasing hormone (GnRH or LH-RH).
Presentation and Composition :
The single dose vial of Leuprolide Acetate for deposit suspension 3.75 mg contains Leuprolide Acetate
(3.75 mg), purified Gelatin (0.65 mg), DL-Lactic and Glycolic acids Copolymer (33.1 mg) and D-Mannitol (6.6 mg)
The single-dose vial of Leuprolide Acetate depot suspension 3 month 11.25 mg contains Leuprolide Acetate (11.25 mg), a polymer, poly (DL-Lactic acid) 99.3 mg and D-Mannitol 19.45 mg.
Indications
Prostate Cancer
Lucrin Depot is indicated in the palliative treatment of
advanced prostatic cancer. It offers an alternative treatment of prostatic cancer when
orchiectomy or estrogen administration are either not indicated or unacceptable to the
patient.
Endometriosis
Lucrin Depot (3.75 mg) is indicated in the treatment of
endometriosis for a period of six months. It can be used as sole therapy or as an adjunct
to surgery.
Uterine Fibroids
Lucrin Depot (3.75 mg) is indicated in the treatment of
leiomyoma uteri (uterine fibroids) for a period of up to six months. Therapy may be
preoperative prior to myomectomy or hysterectomy, or it may provide symptomatic relief
for the perimenopausal woman who does not desire surgery.
For Precautions and Drug Interactions please consult full Product Information / Package Insert.
